Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1922 1
1950 1
1951 1
1953 2
1961 1
1962 1
1965 1
1967 1
1968 1
1970 1
1971 1
1974 1
1978 1
1979 5
1980 2
1981 5
1982 2
1983 2
1984 3
1985 7
1986 6
1987 9
1988 6
1989 10
1990 8
1991 9
1992 11
1993 5
1994 5
1995 7
1996 5
1997 7
1998 12
1999 10
2000 12
2001 8
2002 9
2003 6
2004 4
2005 15
2006 8
2007 11
2008 10
2009 7
2010 16
2011 24
2012 11
2013 13
2014 16
2015 32
2016 25
2017 24
2018 21
2019 15
2020 17
2021 30
2022 22
2023 19
2024 24
2025 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

536 results

Results by year

Filters applied: . Clear all
Page 1
Towards a common definition of surgical prehabilitation: a scoping review of randomised trials.
Fleurent-Grégoire C, Burgess N, McIsaac DI, Chevalier S, Fiore JF Jr, Carli F, Levett D, Moore J, Grocott MP, Copeland R, Edbrooke L, Engel D, Testa GD, Denehy L, Gillis C. Fleurent-Grégoire C, et al. Among authors: copeland r. Br J Anaesth. 2024 Aug;133(2):305-315. doi: 10.1016/j.bja.2024.02.035. Epub 2024 Apr 26. Br J Anaesth. 2024. PMID: 38677949 Free PMC article.
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Fedoriw A, Rajapurkar SR, O'Brien S, Gerhart SV, Mitchell LH, Adams ND, Rioux N, Lingaraj T, Ribich SA, Pappalardi MB, Shah N, Laraio J, Liu Y, Butticello M, Carpenter CL, Creasy C, Korenchuk S, McCabe MT, McHugh CF, Nagarajan R, Wagner C, Zappacosta F, Annan R, Concha NO, Thomas RA, Hart TK, Smith JJ, Copeland RA, Moyer MP, Campbell J, Stickland K, Mills J, Jacques-O'Hagan S, Allain C, Johnston D, Raimondi A, Porter Scott M, Waters N, Swinger K, Boriack-Sjodin A, Riera T, Shapiro G, Chesworth R, Prinjha RK, Kruger RG, Barbash O, Mohammad HP. Fedoriw A, et al. Among authors: copeland ra. Cancer Cell. 2019 Jul 8;36(1):100-114.e25. doi: 10.1016/j.ccell.2019.05.014. Epub 2019 Jun 27. Cancer Cell. 2019. PMID: 31257072 Free article.
A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair.
Castro J, Daniels MH, Brennan D, Johnston B, Gotur D, Lee YT, Knockenhauer KE, Lu C, Wu J, Nayak S, Collins C, Bansal R, Buker SM, Case A, Liu J, Yao S, Sparling BA, Sickmier EA, Silver SJ, Blakemore SJ, Boriack-Sjodin PA, Duncan KW, Ribich S, Copeland RA. Castro J, et al. Among authors: copeland ra. Cancer Res. 2025 Feb 17;85(4):758-776. doi: 10.1158/0008-5472.CAN-24-0397. Cancer Res. 2025. PMID: 39589774 Free PMC article.
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V. Italiano A, et al. Among authors: copeland ra. Lancet Oncol. 2018 May;19(5):649-659. doi: 10.1016/S1470-2045(18)30145-1. Epub 2018 Apr 9. Lancet Oncol. 2018. PMID: 29650362 Clinical Trial.
Novel targets for parkinsonism-depression comorbidity.
Tizabi Y, Getachew B, Csoka AB, Manaye KF, Copeland RL. Tizabi Y, et al. Among authors: copeland rl. Prog Mol Biol Transl Sci. 2019;167:1-24. doi: 10.1016/bs.pmbts.2019.06.004. Epub 2019 Jul 8. Prog Mol Biol Transl Sci. 2019. PMID: 31601399 Review.
Autoantibodies immuno-mechanically modulate platelet contractile force and bleeding risk.
Oshinowo O, Copeland R, Patel A, Shaver N, Fay ME, Jeltuhin R, Xiang Y, Caruso C, Otumala AE, Hernandez S, Delgado P, Dean G, Kelvin JM, Chester D, Brown AC, Dreaden EC, Leong T, Waggoner J, Li R, Ortlund E, Bennett C, Lam WA, Myers DR. Oshinowo O, et al. Among authors: copeland r. Nat Commun. 2024 Nov 25;15(1):10201. doi: 10.1038/s41467-024-54309-8. Nat Commun. 2024. PMID: 39587073 Free PMC article.
The Elements of Translational Chemical Biology.
Copeland RA, Boriack-Sjodin PA. Copeland RA, et al. Cell Chem Biol. 2018 Feb 15;25(2):128-134. doi: 10.1016/j.chembiol.2017.11.003. Epub 2017 Dec 7. Cell Chem Biol. 2018. PMID: 29233521 Free article. Review.
RNA-modifying proteins as anticancer drug targets.
Boriack-Sjodin PA, Ribich S, Copeland RA. Boriack-Sjodin PA, et al. Among authors: copeland ra. Nat Rev Drug Discov. 2018 Jun;17(6):435-453. doi: 10.1038/nrd.2018.71. Epub 2018 May 18. Nat Rev Drug Discov. 2018. PMID: 29773918 Review.
Physical activity for cancer survivors.
Bourke L, Rosario D, Copeland R, Taylor S. Bourke L, et al. Among authors: copeland r. BMJ. 2012 Jan 30;344:d7998. doi: 10.1136/bmj.d7998. BMJ. 2012. PMID: 22294755 No abstract available.
Surviving syndemics - Authors' reply.
Fields EL, Copeland R, Hopkins E, Sanders RA, Malebranche DJ. Fields EL, et al. Among authors: copeland r. Lancet. 2021 Jul 10;398(10295):119. doi: 10.1016/S0140-6736(21)01325-8. Lancet. 2021. PMID: 34246345 No abstract available.
536 results